WSGR logoWSGR logo
Lisa Nip
Patent Agent
Patents and Innovations
Boston

D617-598-7875

Download vCard
Open PDF

Dr. Lisa Nip is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes molecular biology, genetics, protein engineering, biochemistry, and gene editing technologies. Lisa applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.

Prior to joining the firm, Lisa was a scientist working in the immuno-oncology and agricultural biosciences. She completed her doctorate degree at the Massachusetts Institute of Technology, where her work focused on engineering gene-editing systems.

Experience

Dr. Lisa Nip is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes molecular biology, genetics, protein engineering, biochemistry, and gene editing technologies. Lisa applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.

Prior to joining the firm, Lisa was a scientist working in the immuno-oncology and agricultural biosciences. She completed her doctorate degree at the Massachusetts Institute of Technology, where her work focused on engineering gene-editing systems.

Focus Areas
Recent Insights
Client Highlights
Firm Advises Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on Constructive Bio’s $58 Million Series A
On September 24, 2024, Constructive Bio, a pioneering synthetic genomics company, announced that it has secured $58 million in the first close of its Series A financing, bringing the total amount raised by the company to date to $75 million. The round was led by Ahren Innovation Capital, OMX Ventures, and Paladin Capital Group with participation from Fine Structure Ventures, +ND Capital, and Abcam-founder Jonathan Milner. Wilson Sonsini Goodrich & Rosati advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Stoke Therapeutics on IP Matters Related to Upsized Public Offering
On March 28, 2024, Stoke Therapeutics, a biotechnology company focused on developing RNA-based medicines to treat severe diseases, announced the pricing of its upsized underwritten public offering. The company is offering 5,555,557 shares at $13.50 per share and, in lieu of shares to investors that so choose, pre-funded warrants to purchase up to 3,703,730 shares at $13.4999. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares. The gross proceeds from this offering, to be closed on or about April 2, are expected to be $125 million before expenses. Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters related to the transaction.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.